Medical Terminology


« Back to Glossary Index

Atomoxetine (Strattera, Attera, Attentin, Axepta, Axetra, Stramox, Tomoxetin) is a non-stimulant medication approved by the U.S. FDA in 2002 to treat attention-deficit hyperactivity disorder (ADHD). It belongs to the group of medicines called selective norepinephrine reuptake inhibitors (NRIs), and is believed to work by increasing norepinephrine and dopamine. It increases wakefulness, but generally less strongly than the medications which act directly on dopamine. A medication similar to atomoxetine is reboxetine, which is approved in Europe but is not currently approved in the U.S. However, reboxetine was granted Orphan Drug Designation (ODD) status by the FDA in October 2018 for the treatment of narcolepsy. Read more about atomoxetine at HERE and on HF’s Treatment web page HERE.

Strattera, Attera, Attentin, Axepta, Axetra, Stramox, Tomoxetin

The contents of this website, including text, graphics and other material, are for informational purposes only. This website is not intended to be a substitute for professional legal or medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Always consult your own attorney or other legal advisor with any legal questions you may have. The Hypersomnia Foundation does not recommend or endorse any specific tests, physicians, lawyers, legal advisors, products, procedures, opinions or other information referenced on this website. Reliance on any information on this website is solely at your own risk.

The Hypersomnia Foundation makes no representations or warranties about the satisfaction of any government regulations requiring disclosure of information on prescription drug products. In no event shall The Hypersomnia Foundation be liable for any damages (including without limitation incidental and consequential damages) or costs (including without limitation attorney’s fees) based on any claim arising from the use of this website and/or its content.